CM
TAK icon

Capula Management’s Takeda Pharmaceutical TAK Stock Holding History

Capula Management’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-896,900
Closed -$16.4M – 870
2021
Q1 		$16.4M Buy
+896,900
New +$16.1M 0.32% 92

Other funds holding TAK

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Capula Management's TAK Position: Q2 2021 in Review

Capula Management sold out of Takeda Pharmaceutical (TAK) in Q2 2021, closing a stake of 190,742 shares — an estimated $3.48M sold.

Capula Management first reported a position in TAK in Q1 2021 and held it in 1 quarter. The position peaked at $3.48M in Q1 2021. 304 funds tracked by Wall St. Rank hold TAK as of Q2 2021.

  • Capula Management reported no remaining Takeda Pharmaceutical position as of Q2 2021 after selling out during the quarter.
  • Capula Management sold 190,742 Takeda Pharmaceutical shares in Q2 2021, an estimated $3.48M.
  • Capula Management first reported a position in Takeda Pharmaceutical in Q1 2021 and held it in 1 quarter.
  • Capula Management's Takeda Pharmaceutical position peaked at $3.48M in Q1 2021.
  • 304 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2021.

Based on Capula Management's 13F filing for Q2 2021, filed 13 Aug 2021.